Previous 10 | Next 10 |
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the company’s participation at the Immuno Series US Virtual meeting which will be held online, October 15-16, 2020. Personalis will present “Maximizing immunotherapy biomarke...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the company’s participation at IO Combinations 360˚ which will be held online, October 1-2, 2020. The presentation, titled “Comprehensive immunogenomics to enable comp...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the company’s participation at the Digital World CB & CDx meeting which will be held online, September 29-October 1, 2020. Personalis will present “Enabling the Expansive...
A resistance line has formed in the chart of Personalis (PSNL). As the stock test its high, look for a breakout. Learn when to enter a long position. Shares of Personalis ( PSNL ) could see a strong move higher soon. That’s because a key resistance level has formed on the sto...
Personalis (NASDAQ: PSNL ) has announced that the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP) has exercised its option to extend its existing contract through September 2021. More news on: Personalis, Inc., Healthcare stocks news, Read more ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, announces that the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP) has exercised its option to extend our existing contract through September 2021. The VA also issued a ne...
Number of whole genomes sequenced surpasses 87,000, targeting 100,000 by year end Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the appointment of Kevin Dunne as its new Head of Population Genomics. Mr. Dunne bri...
I have been specializing myself in the insider topic with months of empirical research to understand the trades and their informativeness. Insiders are the high managers, directors and majority shareholders of a firm and know their company better than anyone else as they are close to the s...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the following upcoming investor conferences. H.C. Wainwright 22nd Annual Global Investment Conference Presenting on Wednesday, September 16 at 11 a.m. ...
Investment thesis With the recent launch of Liquid Biopsy, China expansion, machine learning platform later in the year and a slight pivot to attempting to sell population sequencing to more countries, Personalis has become an even more enticing opportunity. Developments since IPO O...
News, Short Squeeze, Breakout and More Instantly...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2024 financial results on Wednesday, August 7, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tum...